Seelos Therapeutics is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and other neurodegenerative diseases
The company is engaged in advancing a diverse pipeline of product candidates that aim to address significant unmet medical needs, leveraging scientific research and clinical expertise to offer potential solutions for conditions such as depression, anxiety, and traumatic brain injury. Seelos is committed to harnessing the power of cutting-edge technologies to improve the lives of patients and provide new options for treatment.
Interest in psychedelics and their therapeutic potential has grown in recent years, and plenty of studies have been conducted or are currently underway to understand how exactly these substances exert the effects they have. One recent study focused on why some people report experiencing difficult emotions, such as guilt and shame, during their psychedelic sessions and what impact those feelings have on their wellbeing in the days, weeks and months after psychedelic use.
Seelos Therapeutics announces delisting from Nasdaq due to failure to meet equity requirements, with trading set to shift to OTC markets on October 16, 2024.
Seelos shares are trading higher Tuesday after the company announced that it signed a material transfer agreement to supply SLS-002 for the Department of Defense's Military and Veterans Adaptative Platform Clinical Trial for PTSD.
